ALVO
Alvotech NASDAQ Listed Jun 16, 2022$3.57
After hrs
$3.24
-9.24%
Mkt Cap $1.1B
52w Low $3.03
6.1% of range
52w High $11.85
50d MA $3.61
200d MA $5.94
P/E (TTM)
34.6x
EV/EBITDA
8.4x
P/B
—
Debt/Equity
-5.1x
ROE
—
P/FCF
-12.5x
RSI (14)
—
ATR (14)
—
Beta
0.25
50d MA
$3.61
200d MA
$5.94
Avg Volume
554.0K
About
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arth…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 18, 2026 | AMC | -0.01 | -0.37 | -6335.7% | 3.80 | -3.7% | -5.8% | -7.1% | -12.4% | -17.6% | -17.4% | — |
| Nov 12, 2025 | AMC | 0.05 | -0.02 | -140.0% | 5.60 | -7.0% | -1.4% | -2.0% | -8.2% | -8.8% | -6.6% | — |
| Aug 13, 2025 | AMC | -0.26 | 0.14 | +153.8% | 8.96 | -1.2% | -5.4% | -10.4% | +0.4% | -3.0% | -8.3% | — |
| May 7, 2025 | AMC | -0.17 | 0.35 | +305.9% | 7.94 | +17.1% | +18.1% | +21.9% | +29.1% | +33.0% | +32.2% | — |
| Mar 26, 2025 | AMC | -0.39 | -0.24 | +38.5% | 11.55 | -0.7% | -10.3% | -17.3% | -16.3% | -16.5% | -20.4% | — |
| Nov 13, 2024 | AMC | -0.06 | 0.19 | +401.6% | 11.93 | +5.4% | +1.2% | -1.7% | +1.4% | +4.8% | +4.1% | — |
| Aug 15, 2024 | AMC | -0.28 | 0.28 | +200.0% | 11.93 | +6.0% | +8.7% | +8.9% | +6.0% | +3.9% | +0.3% | — |
| May 21, 2024 | AMC | -0.08 | -0.89 | -972.3% | 13.94 | +1.5% | +0.4% | -2.6% | +1.8% | +0.4% | -2.4% | — |
| Mar 20, 2024 | AMC | 0.15 | -1.22 | -913.3% | 15.23 | -1.6% | -1.1% | -1.8% | -12.9% | -17.9% | -16.7% | — |
| Nov 28, 2023 | AMC | -0.29 | -0.82 | -182.8% | 9.80 | +1.0% | -4.1% | -3.1% | -3.6% | -3.2% | -4.6% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 24 | Barclays | Maintains | Underweight → Underweight | — | $3.33 | $3.28 | -1.5% | -6.0% | -5.7% | -2.7% | -6.6% | -1.2% |
| Mar 24 | UBS | Maintains | Buy → Buy | — | $3.33 | $3.28 | -1.5% | -6.0% | -5.7% | -2.7% | -6.6% | -1.2% |
| Nov 18 | UBS | Maintains | Buy → Buy | — | $5.14 | $5.11 | -0.6% | -0.6% | +1.8% | -1.6% | +0.0% | +6.4% |
| Nov 4 | Deutsche Bank | Downgrade | Buy → Hold | — | $5.03 | $5.09 | +1.2% | -4.0% | -3.0% | +0.6% | +13.5% | +8.9% |
| Oct 14 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $7.97 | $8.30 | +4.1% | +6.6% | +12.7% | +9.8% | +9.4% | +7.8% |
| Sep 23 | Deutsche Bank | Upgrade | Hold → Buy | — | $8.01 | $8.35 | +4.2% | +8.6% | +7.1% | +1.4% | +4.1% | +4.9% |
| Jul 18 | UBS | Maintains | Buy → Buy | — | $8.73 | $8.75 | +0.2% | -1.1% | -1.0% | -0.6% | +4.9% | +4.9% |
| Jul 25 | Barclays | Maintains | Overweight → Overweight | — | $11.60 | $11.60 | +0.0% | -2.7% | -0.1% | +1.8% | +1.7% | +0.9% |
| May 24 | Barclays | Maintains | Overweight → Overweight | — | $13.58 | $13.70 | +0.9% | +4.5% | +3.0% | +0.1% | +1.4% | +2.2% |
| Mar 22 | Barclays | Maintains | Overweight → Overweight | — | $15.07 | $15.00 | -0.5% | -0.8% | -11.9% | -17.1% | -15.9% | -18.9% |
Data updated apr 24, 2026 5:36pm
· Source: massive.com